NCT07362030Active, not recruitingPhase 1
Drug-durg Interaction of RAY1225 With Warfarin, Atorvastatin, Metformin and Digoxin
A Open-Label, Phase I Drug-drug Interaction Clinical Study to Investigate the Pharmacokinetics of RAY1225 With Warfarin, Atorvastatin, Metformin and Digoxin in Healthy Participants
Source: ClinicalTrials.gov · Last updated 23 Jan 2026
Brief summary (registry, in English)
The drug-drug interaction study had been designed to investigate the effect of RAY1225 on the pharmacokinetics of digoxin, Rosuvastatin and
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 32 (actual)
- First submitted
- 14 Jan 2026
- Start date
- 14 Apr 2025
- Primary completion date
- 27 Dec 2025
- Lead sponsor
- Guangdong Raynovent Biotech Co., Ltd
- Diseases
- Obesity
- NCT number
- NCT07362030
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 32
- From 14 Apr 2025 to the primary completion date, 27 Dec 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Participants had taken prescription, over-the-counter, herbal, or vitamin products within 4 weeks prior to screening；
- Smoking more than 5 cigarettes per day within 12 weeks prior to screening，or who cannot stop using any tobacco products during the study period;
- Participants who donated blood/bleeding profusely (\> 400 mL) 12 weeks prior to randomization;
Other illness
- Participants with a history of hypersensitivity to study drug or any component of study medication;
- History of dysphagia or any gastrointestinal disorder that affect absorption
Other
- Those with clinically significant Electrocardiogram(ECG) abnormalities, or QTcF \> 450ms;
- Participants who test positive at Screening and/or admission (Day -1) for alcohol abuse.
- Females who are pregnant, lactating, or likely to become pregnant during the study.
Who the study is looking for
- Body mass index (BMI) ≥20 to ≤35 kg/m2 and total body weight \>50 kg(male) or \>45kg(female) at Screening (calculated as a function of measured height and weight according to the formula, BMI = kg / m2 where m2 is height in meters squared);
- Ability to understand and willingness to sign a written informed consent form;
- Normal physical examination, vital signs, 12-lead ECG, and clinical laboratory values, or any abnormality that is non-clinically significant.
Age in the registry: 18 years to 55 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Dongguan People's Hospital Coordinator of this site? Confirm its status | Dongguan | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.